Image de couverture de livre

Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma?

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Cuiyun Tao, Ye Liang, Jianghui Zeng
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Resmetirom for treatment of MASH with children and adolescents
par: Yong‐Hai Zhou, et autres
Publié: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
par: Jannis Kountouras, et autres
Publié: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
par: S. K. Bansal, et autres
Publié: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
par: Xiao‐Dong Zhou, et autres
Publié: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
par: Eric Lawitz, et autres
Publié: (2025)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
par: Nikita Mittal, et autres
Publié: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
par: Carolin V. Schneider, et autres
Publié: (2024)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
par: Matheus Souza, et autres
Publié: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
par: Veeral Ajmera, et autres
Publié: (2026)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
par: Leon A. Adams, et autres
Publié: (2026)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
par: Matheus Souza, et autres
Publié: (2026)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
par: Senlin Ye, et autres
Publié: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
par: Xiaojuan Liu, et autres
Publié: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
par: Liang Jiao, et autres
Publié: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
par: Ao Gao, et autres
Publié: (2026)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
par: Jian Wang, et autres
Publié: (2024)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
par: Manjeet Kumar Goyal, et autres
Publié: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
par: Muhammad Osama, et autres
Publié: (2024)

Letter: Irritable bowel syndrome and antibiotics
par: George F. Longstreth
Publié: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
par: Kacie H. Denton, et autres
Publié: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
par: Louise J. M. Alferink, et autres
Publié: (2024)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
par: Joëlle St‐Pierre, et autres
Publié: (2026)

Letter: Steroid Tapering—Is Shorter Duration Better?
par: Juntao Lu, et autres
Publié: (2026)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
par: Jian Wang, et autres
Publié: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
par: Weilun Gao, et autres
Publié: (2024)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
par: Hassan Javed, et autres
Publié: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
par: Richard Pollok
Publié: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
par: Fernanda Cristofori, et autres
Publié: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
par: Mathieu Uzzan, et autres
Publié: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
par: Ewan Forrest, et autres
Publié: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
par: Kyle Staller, et autres
Publié: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
par: Christophe Corpechot
Publié: (2026)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
par: Mustafa Mohamedrashed, et autres
Publié: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
par: Tamar Schildkraut, et autres
Publié: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
par: Ting Wang, et autres
Publié: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
par: Maryam Kharal, et autres
Publié: (2024)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
par: Mo‐Yao Tan, et autres
Publié: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
par: Péter Bacsur, et autres
Publié: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
par: Jiru Li, et autres
Publié: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
par: Kuan‐Ju Lin, et autres
Publié: (2025)